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Abstract
Purpose: Controversy exists whether the prostate-specific antigen (PSA) bounce phenomenon following definitive 
radiation for prostate cancer has prognostic significance. Here, we perform a meta-analysis to determine the associa-
tion between PSA bounce and biochemical control after brachytherapy alone. 
Material and methods: We reviewed Medline, EMBASE, and CENTRAL citations through February 2012. Studies 
that recorded biochemical failure rates in bouncers and non-bouncers were included. Hazard ratios describing the im-
pact of bounce on biochemical failure were extracted directly from the studies or calculated from survival curves. Pooled 
estimates were obtained using the inverse variance method. A random effects model was used in cases of significant 
effect heterogeneity (p < 0.10 using Q test). 
Results: The final analysis included 3011 patients over 6 studies treated with brachytherapy. Meta-analysis revealed 
that patients experiencing PSA bounce after brachytherapy, conferred a decreased risk of biochemical failure (random 
effects model HR = 0.42, 95% CI: 0.30-0.59; p < 0.001). 
Conclusions: Our meta-analysis determined that PSA bounce predicts for improved biochemical control following 
brachytherapy. To our knowledge, this is the first study describing this effect.
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Purpose
The National Comprehensive Cancer Network guide-
lines recommend prostate-specific antigen (PSA) testing 
every six to twelve months after definitive radiation ther-
apy for prostate cancer to assess a patient’s disease status. 
Following treatment with brachytherapy, decline of PSA 
levels to an eventual nadir may take up to five years [1]. 
In up to 30-40% patients receiving prostate brachytherapy 
[2,3], PSA levels may fluctuate without any apparent signs 
of disease recurrence or progression, which is referred 
to as a PSA bounce. While PSA bounce is a well-known 
physiologic phenomenon, its etiology remains unclear. 
Certain studies have reported that age [3-7], prostate vol-
ume and dosimetry [1,6,8], and pre-treatment PSA [9] may 
predict for a post-radiation PSA bounce. Other precipitat-
ing factors may include ejaculations, instrumentations, or 
prostatitis [10]. 
While the potential causes of a PSA bounce are con-
tinuously being investigated, the clinical significance 
of a PSA bounce remains highly controversial. Certain 
studies have failed to show an association between 
the presence of a bounce and biochemical failure [3,9]. 
Conversely, a recent study found the presence of a PSA 
bounce after prostate brachytherapy is strongly related to 
better outcomes not only in terms of biochemical failure, 
but also translated to an overall survival benefit [11]. Be-
cause of considerable disagreement regarding the prog-
nostic significance of a PSA bounce and the consequent 
concern that a rising PSA result engenders in patients 
and treating physicians, we performed an up-to-date 
meta-analysis of published reports to determine wheth-
er any correlation between PSA bounce and biochemi-
cal failure exists after definitive brachytherapy alone in 
prostate cancer patients.  
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Material and methods
Selection of studies
We reviewed relevant Medline, EMBASE, and the Co-
chrane Central Register of Controlled Trials (CENTRAL) 
citations through February 2012. The search terms used 
were “PSA bounce” and “PSA bouncing”, and returned 
results were limited to reports published in English. Stud-
ies that included patients with non-metastatic prostate 
cancer, and reported rates of biochemical failure in pa-
tients with and without PSA bounces after brachythera-
py alone were analyzed. Reviews, supplements, and case 
reports were excluded. Studies that utilized radiotherapy 
techniques other than brachytherapy (i.e. external beam 
radiotherapy [EBRT], stereotactic body radiation therapy or 
high-intensity focused ultrasound) or combined modality 
therapy were also excluded. Of note, in one study that 
was included in the brachytherapy analysis, 4 patients 
also received EBRT as part of their therapy [8]. However, 
this study was still included in our final data set as these 
patients only represented 0.001% of the study population. 
When more than one publication was identified from the 
same study population, the most recent data were used in 
the final analysis.
Data extraction
Data extraction was conducted independently by two 
investigators (M.B.B. and N.O.) according to the Preferred 
Reporting Items for Systematic Reviews and Meta-anal-
yses (PRISMA) statement [12]. We recorded the first au-
thor’s last name, journal name and year of publication, 
in clusion criteria, number of patients, and median age, 
pre-treatment characteristics, median follow-up, treatment 
moda lity, and dose, androgen deprivation therapy (ADT) 
use, definitions of PSA bounce and biochemical failure, 
bounce rates, peak bounce values, and median time to first 
bounce. When multiple definitions for PSA bounce and 
biochemical recurrence were presented in a single publica-
tion, the most commonly used definitions in the literature 
(i.e. a rise of 0.2 ng/mL and the ASTRO-Phoenix defini-
tion) were chosen whenever possible.
Hazard ratios (HRs) for biochemical failure associated 
with PSA bounce were extracted directly from the orig-
inal studies or were estimated indirectly by reading off 
survival curves as suggested by Parmar et al. [13]. Data 
extraction from survival curves and estimations of effect 
sizes were performed using customized scripts in Matlab 
(The Mathworks, Natick, MA, U.S.A.). 
Statistical analysis
Meta-analysis was performed using the inverse vari-
ance method. The Cochran Q statistic was used to assess 
statistical heterogeneity in effect sizes across trials. The 
as sumption of homogeneity was considered invalid for 
p-values less than 0.10. This prompted the use of the ran-
dom-effects model to derive summary estimates for HRs 
and 95% CIs. Publication bias was evaluated visually with 
funnel plots and statistically using the Egger test [14]. 
A two-tailed p-value of less than 0.10 was considered sta-
tistically significant. 
Results
Selection of studies
Using the aforementioned search terms, a total of 115 
studies (44 from Medline, 71 from EMBASE, and 0 from 
Cochrane Central Register of Controlled Trials) were in-
itially returned. After excluding articles for not meeting 
the criteria detailed in Material and methods, 23 studies 
were read carefully in their entirety. As shown in Figure 1, 
17 studies were excluded either for not recording bio-
chemical failure rates in patients with and without PSA 
bounce or because of a more recent publication reporting 
on the same study population. Ultimately, six brachyther-
apy studies [1,5-8,11] were included in the final analysis. 
The characteristics of each study are shown in Table 1. 
47 excluded
 25  supplements/commentary/
case report
 7 combined modality
 4 reviews
 3 EBRT
 2 SBRT
 1 HIFU
 2  etiology of PSA bounce/ 
accuracy of bounce definitions
 3 other
17 excluded
 10  no correlation of PSA  
bounce rates with BF
 7  patient population included 
in a pooled analysis or a more 
recent publication
45 excluded (duplicate studies)
70 potentially relevant articles  
screened based on abstracts
23 full text articles assessed  
for inclusion
6 studies included in meta-analysis
EBRT – external beam radiation therapy, SBRT – stereotactic body 
radiation therapy, HIFU – high-intensity focused ultrasound,  
PSA – prostate-specific antigen, BF – biochemical failure 
Fig. 1. Selection of studies
115 articles identified
 44 Medline
 71 EMBASE
   0  Cochrane Central Register  
of Controlled Trials
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PrognosticsignificanceofPSAbouncefollowing
brachytherapy
There were a total of 3011 patients treated with brachy-
therapy (125I or 103Pd) as a monotherapy in the six studies 
included in the final analysis. In five out of six reports, 
the ASTRO-Phoenix definition (≥ 2 ng/mL above PSA na-
dir) was used for biochemical failure and a rise of 0.2 ng/
mL above a nadir defined a PSA bounce. One study used 
a rise of ≥ 0.1 ng/mL for the bounce threshold and the 
ASTRO consensus definition for biochemical failure [6]. 
Median follow-up ranged from 45 to 72 months, with 
a median time to first bounce between 17.4 and 19.5 
months. PSA bounce rates were recorded in 27.4-50% of 
patients. There was evidence of heterogeneity between 
study results (Cochrane’s Q = 10.25, p = 0.086). Random 
effects meta-analysis revealed that experiencing a PSA 
bounce after brachytherapy was associated with a statis-
tically significant decrease in the risk of biochemical fail-
ure (HR = 0.42, 95% CI: 0.30-0.59; p < 0.001). Meta-analysis 
results are shown in Figure 2. No evidence of publication 
bias was detected using the Egger test (p = 0.947). 
Discussion
Although the PSA bounce phenomenon has been well- 
described for years, its potential implication on biochem-
ical control remains highly controversial. Select studies 
have shown improved rates of biochemical control in 
patients experiencing PSA bounce after brachytherapy 
alone [1], while other investigators have shown an in-
creased incidence of biochemical recurrence in bouncers 
[4,15]. Additionally, certain studies have failed to confirm 
PSA bounce as a prognostic indicator [3,9]. Thus, we per-
formed an up-to-date systematic review and meta-analy-
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Hazard ratio for biochemical failure after PSA bounce
Mitchell et al. [5]
Stock et al. [6]
Hinnen et al. [11]
Caloglu et al. [1]
Zwahlen et al. [7]
Aaltomaa et al. [8]
Combined
PSA – prostate-specific antigen
The hazard ratios of biochemical recurrence after brachytherapy were 
calculated using a random-effects model (HR = 0.42, 95% CI: 0.30-
0.59, p < 0.001]. The diamond indicates the summary hazard ratio
Fig. 2. Forest plot of brachytherapy trials
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sis to determine if a post-radiation PSA bounce impacts 
bio chemical control in prostate cancer patients treated 
with single modality therapy. 
Our meta-analysis revealed that PSA bounce predicted 
for improved biochemical control following brachy therapy. 
The final analysis included six studies totalling 3011 patients 
treated with 125I or 103Pd as a monotherapy, and showed 
a statistically significant decrease in recurrence rates in pa-
tients meeting the threshold for PSA bounce. In all but one 
study, bounce was defined as a rise of ≥ 0.2 ng/mL above 
a nadir and the ASTRO-Phoenix criteria was used to define 
biochemical recurrence. Stock et al. defined bounce as a rise 
of ≥ 0.1 ng/mL above PSA nadir and used the ASTRO con-
sensus definition for biochemical failure [6]. Had this study 
been excluded from the final analysis for consistency, the 
above findings would have remained the same (data not 
shown). Our findings are consistent with a recent publica-
tion that analyzed the clinicopathological and post-dosime-
tric parameters predictors of PSA bounce. In that report, no 
patient with PSA bounce after low-dose rate brachytherapy 
experienced biochemical recurrence, while 10/150 patients 
that did not meet the criteria for bounce were diagnosed 
with biochemical recurrence [16]. 
Interestingly, a large multi-institutional study by Hor-
witz et al., which pooled 4839 patients from nine institu-
tions treated with external beam radiation therapy alone 
showed the opposite result, reporting biochemical con-
trol rates of 58% versus 72% at 10 years for bouncers and 
non-bouncers, respectively [4]. The contrasting implica-
tions of PSA bounce following EBRT found in that study 
compared to the conclusions that we report following 
brachytherapy have not been previously described. Some 
have theorized that PSA bounce is a positive prognostic 
factor because it signifies lethal en-mass cellular death and 
a favourable physiologic response to radiation therapy [17]. 
This phenomenon may be more likely after brachytherapy, 
where focal areas of the prostate and stroma are exposed 
to ablative radiotherapy doses that promote apoptotic cell 
death [18]. A second hypothesis is that the heterogeneous 
dose distribution of brachytherapy may promote late radi-
onecrosis within the prostate. The resulting release of tu-
mor-specific antigens into the bloodstream may stimulate 
a directed immune response, similar to the intensive lym-
phocytic infiltration into brain tumors seen after treatment 
with Gamma Knife radiosurgery [19]. Fractionated EBRT, 
on the other hand, is unlikely to be associated with these 
effects, which manifests clinically as lower rates of bounce, 
earlier time to bounce, and shorter duration of bounce [6] 
such that a PSA rise after therapy may represent true tu-
mor regeneration. 
While bounce rates are less frequent following EBRT, 
discrepancy exists when comparing bounce frequency fol-
lowing treatment with LDR versus HDR brachytherapy. 
According to a report from Pinkawa et al., PSA bounce 
rates were significantly higher following LDR brachy-
therapy compared to HDR brachytherapy (42% vs. 23%, 
respectively). Bounces > 1 ng/mL were also more frequent 
after LDR than HDR brachytherapy [20]. The authors 
suggest that local inflammatory effects may play a major 
role for the predominant induction of bounces after LDR 
brachytherapy – even in contrast to HDR brachytherapy. 
Conversely, a more recent study reported bounce rates as 
high as 43% following HDR brachytherapy [21]. Perhaps 
these findings can be explained by examining the simi-
larities and differences between these two techniques, 
including the ease of administration, side effect profile, 
dosimetry, and radiobiological implications [22]. Clearly, 
additional studies are necessary to reconcile these obser-
vations. 
Regardless of the treatment modality, several patient 
characteristics that may predict for a post-radiation PSA 
bounce have been described, including risk group strat-
ification, pretreatment PSA, Gleason score, PSA nadir, 
the use of androgen ablation, and dose to the prostate 
[2,3,6,10]. Despite dose escalation with EBRT, the recom-
mended 125I monotherapy prescription dose for a prostate 
implant is 144 Gy – nearly twice what can be achieved 
with EBRT. Perhaps it is simply the higher dose to the 
prostate that can account for the increase in PSA bounce 
rates with brachytherapy. This brachytherapy prescrip-
tion, however, has been recently called into question, and 
thus higher dose prescriptions for these implants may be 
on the horizon, potentially leading toward more patients 
experiencing a bounce [23].
Nevertheless, the clinical factor that appears most con-
sistently to predict for PSA bounce after EBRT [4,24] or 
brachytherapy [3,5-8,11] is younger age. Increased sexually 
activity in this patient population has been proposed as one 
possible explanation for this observation [2,10]. Alternative-
ly, a delayed apoptotic event may simply be more common 
in younger individuals [2]. Caloglu et al. also discussed 
that younger patients may have more androgen produc-
tion and more reactive epithelial cells, which may increase 
the incidence of the bounce phenomenon [1,6]. Similarly, 
Akyol et al. described a direct relationship between rising 
testosterone levels and the occurrence of a PSA bounce, 
thereby suggesting that younger patients with higher tes-
tosterone levels may experience higher rates of PSA bounce 
[9]. As seen in Table 1, the brachytherapy series typically 
include younger men when compared to the EBRT litera-
ture, which may explain why most brachytherapy studies 
do a report a higher bounce rate than those using the EBRT 
technique. In addition to age, a lower threshold value used 
to meet the criteria for a bounce after brachytherapy may 
contribute as well since a PSA rise of ≥ 0.2 ng/mL to signal 
a bounce after brachytherapy, and ≥ 0.4 ng/mL following 
EBRT appear to be the most widely accepted definitions in 
the literature [2,4,6,11,15]. 
We acknowledge that a potential limitation of our 
study is the use of different definitions for PSA bounce 
and biochemical failure for one of the brachytherapy pa-
pers included in our final analysis [6]. Some prior studies 
have confirmed the rates of bounce and biochemical con-
trol will be affected by which criteria are chosen [1,6,7]. 
Nevertheless, no study was excluded in our final analysis 
based on definitions alone, and when multiple definitions 
for bounce and biochemical recurrence were included 
in one study, the aforementioned definitions were cho-
sen whenever possible. While a single definition of PSA 
bounce would be more appealing, the optimal characteri-
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zation for this phenomenon remains undefined. The same 
report also included patients treated with 103Pd as the 
source, while all others treated patients with 125I [6]. How-
ever, those patients only accounted for 1.2% of our study 
population. Additionally, as stated above, 4 patients in 
one study received EBRT plus brachytherapy. This report 
was included in the final analysis as it only represented 
4/3011 (0.001%) of our study population. Furthermore, 
when this study was excluded from the meta-analysis, our 
findings remained the same (data not shown). Lastly, we 
could not assess the impact of bounce on other endpoints, 
such as distant metastases or overall survival, because 
these relationships are rarely reported in existing papers. 
Interestingly, Hinnen et al. found that bounce after pros-
tate brachytherapy was related improved disease-specific 
survival and overall survival [11]. While understanding 
how PSA bounce affects development of distant metasta-
ses and overall survival would be informative, identify-
ing its impact on biochemical progression-free survival is 
useful since patients are frequently salvaged with ADT, 
which can be associated with decreased quality of life [25]. 
Conclusions
Significance discordance currently exists in the liter-
ature whether PSA bounce has prognostic significance. 
Because this phenomenon occurs in many as 50% after 
brachytherapy [7], understanding its potential clinical 
relevance may be important when counselling patients 
regarding their future cancer care. Our meta-analysis 
showed that PSA bounce is a positive prognostic factor 
after brachytherapy and predicts for increased rates of 
biochemical control. To our knowledge, this is the first 
meta-analysis investigating this issue. 
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